Session Information
-
WCLC 2018
19th World Conference on Lung Cancer
Conference Program for the 19th World Conference on Lung Cancer in Toronto, Canada
Download PDF of the Abstract Book: Click Here.
Presentation Date(s):- Sept 23 - 26, 2018
- Total Presentations: 2391
September 23 Sun
Sep 23 Monday
September 24 Mon
Sep 24 Tuesday
September 25 Tue
Sep 25 Wednesday
September 26 Wed
Sep 26
-
+
MA02 - Improving Outcomes for Patients with Lung Cancer
- 10:30 - 12:00
- 9/24/2018
- Location: Room 201 BD
- Type: Mini Oral Abstract Session
- Track: Advanced NSCLC
-
+
MA02.10 - The First Year of Implementing a Lung Cancer Screening Program in an Urban Safety-Net Health System
11:35 - 11:40 | Presenter: Heidi Hamann | Author(s): Simon Lee, Travis Browning, Claudia Chavez, Joanne Sanders, Suhny Abbara, David Balis, Hsienchang Chiu, Brett Moran, Noel Santini, David E Gerber
- Abstract
Loading...
-
+
MA05 - Improving Outcomes in Locoregional NSCLC II
- 13:30 - 15:00
- 9/24/2018
- Location: Room 105
- Type: Mini Oral Abstract Session
- Track: Treatment of Locoregional Disease - NSCLC
-
+
MA05.01 - E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC
13:30 - 13:35 | Presenter: Jyoti Patel | Author(s): Ju-Whei Lee, Henry Wagner Jr, David P Carbone, Anil Shanker, Leora Horn, Melissa L. Johnson, David E Gerber, Jane Jijun Liu, Millie S Das, Mohammad Ali Al-Nsour, Christopher S R Dakhil, Suresh S. Ramalingam, Joan Schiller
- Abstract
Loading...
-
+
MS07 - Antibody-Drug Conjugates in Advanced NSCLC
- 13:30 - 15:00
- 9/24/2018
- Location: Room 205 BD
- Type: Mini Symposium
- Track: Advanced NSCLC
-
+
MS07.01 - Basic Science
13:30 - 13:50 | Presenter: David E Gerber
- Abstract
No abstract available for this presentation
-
+
P1.01 - Advanced NSCLC (Not CME Accredited Session)
- 16:45 - 18:00
- 9/24/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
-
+
P1.01-02 - Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
16:45 - 18:00 | Presenter: Scott J Antonia | Author(s): Scott N. Gettinger, Hossein Borghaei, Jonathan W. Goldman, Julie R. Brahmer, Neal E. Ready, David E Gerber, Laura Q Chow, Rosalyn Juergens, Scott A. Laurie, Frances A Shepherd, Xuemei Li, Ang Li, William J. Geese, Matthew D. Hellmann
- Abstract
Loading...
-
+
P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session)
- 16:45 - 18:00
- 9/24/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
-
+
P1.16-47 - Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216)
16:45 - 18:00 | Presenter: Geoffrey R. Oxnard | Author(s): Sumithra Mandrekar, Shauna Hillman, Angelina Tan, Ramaswamy Govindan, Dennis Wigle, Shakun Malik, Colleen Watt, David E Gerber, Jamie E Chaft, Suzanne Dahlberg, Karen Kelly, Meredith Faggen, Philip Stella, Karim Tazi, David R. Gandara, Suresh S. Ramalingam, Thomas E. Stinchcombe
- Abstract
Loading...
-
+
MA14 - Survivorship, Socioeconomic and End-of-Life Considerations
- 10:30 - 12:00
- 9/25/2018
- Location: Room 205 BD
- Type: Mini Oral Abstract Session
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
-
+
MA14.10 - QTc Interval-Prolonging Medications in Lung Cancer: Implications for Clinical Trial Eligibility and Routine Clinical Care
11:35 - 11:40 | Presenter: David E Gerber
- Abstract
Loading...
-
+
P2.01 - Advanced NSCLC (Not CME Accredited Session)
- 16:45 - 18:00
- 9/25/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
-
+
P2.01-37 - A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC
16:45 - 18:00 | Presenter: David E Gerber | Author(s): Sawsan Rashdan, Jessica Williams, Penny Currykosky, Farjana Fattah, Jonathan Padro Arroyo, Rebecca Smith, Robert Holt, Rolf Brekken
- Abstract
Loading...
-
+
P2.13 - Targeted Therapy (Not CME Accredited Session)
- 16:45 - 18:00
- 9/25/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
-
+
P2.13-10 - Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC
16:45 - 18:00 | Presenter: Lauren Byers | Author(s): Kathryn Gold, Julio Peguero, Melissa L. Johnson, Jorge Nieva, Wael A Harb, Alberto A. Chiappori, James Strauss, David E Gerber
- Abstract
Loading...